Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AZD1163 in moderately-to-severely active rheumatoid arthritis
jRCT2031250842Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of AZD1163 in rheumatoid arthritis (RA) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in DAS28-CRP at Week 12. Started May 2026; status: recruiting.
02
Drugs
AZD1163
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2031250842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250842.